Population
One white male from the UK with common variable immunodeficiency excreting type 2 vaccine-derived poliovirus…
Design
Case_report
Follow-up
28 years
Authors
Loading...
Alerts to chronic VDPV excretion risk in immunodeficiency; leaves open whether stable vaccines are needed post-eradication.
This case highlights the risk of chronic vaccine-derived poliovirus excretion in immunodeficient individuals and the potential need for new stable live-attenuated polio vaccines in the post-eradication era.
Dunn et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: